The possible advantage of adding cisplatin (P) to cyclophosphamide (C) + adriamycin (A) in the management of stages III and IV ovarian cancer of epithelial origin was tested in a trial in which 149 patients were randomized to receive, after initial surgery, either CAP (C=600 mg/sqm, A=45 mg/sqm, P=50 mg/sqm) or CA (C=600 mg/sqm, A=45 mg/sqm) every 4 weeks for 6 to 12 cycles, at which time follow-up laparotomy was to be performed in responding or clinically disease-free patients. Fifteen patients were not included in the final analysis and the remaining 134 patients were considered fully or partially evaluable and are used in analysis of response and survival. The complete and partial response rates were 45.6% in the CAP arm and 45.4% in the CA arm, but the CAP regimen is of special importance in patients with bulky disease. Median survival CAP=24 m and CA=24.2 m), time to progression and survival was found not significantly different when CAP and CA were compared. However, more patients in the CA regimen had no macroscopic disease left after surgery than in CAP regimen (11 versus 6) and more patients in the CAP arm had dose reductions and schedule delays than in the CA arm (61.1% versus 38.2%).
|Number of pages||8|
|Journal||European Journal of Gynaecological Oncology|
|Publication status||Published - 1990|
ASJC Scopus subject areas
- Obstetrics and Gynaecology